- Home
- TASK vs GERN Comparison
TASK vs GERN Comparison
Compare TASK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TASK | GERN |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 969.3M | 1.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TASK | GERN |
|---|---|---|
| Price | $10.38 | $1.66 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $14.90 | $2.17 |
| AVG Volume (30 Days) | 684.1K | ★ 18.3M |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.12 | $26.91 |
| Revenue Next Year | $6.77 | $43.75 |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $1.04 |
| 52 Week High | $18.39 | $2.01 |
Technical Indicators
Market Signals| Indicator | TASK | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 53.44 |
| Support Level | $9.78 | $1.20 |
| Resistance Level | $11.76 | $1.68 |
| Average True Range (ATR) | 0.49 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 27.27 | 57.95 |
Price Performance
Historical ComparisonAbout TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world-wide Game-changing companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.